...

IEDAT Intra Erythrocyte Dexamethasone in the treatment of Ataxia Telangiectasia

The ATTEST trial will involve more than 20 centers worldwide and should allow to collect relevant safety and efficacy data for regulatory filing to obtain market authorization in the EU and the USA by 2019.

As part of the IEDAT project, additional scientific activities along with ATTEST will be conducted.

The Ataxia Telangiectasia Society will be in charge of the register design and development.

b) A neurological scale specific for AT (AT-NEST) will be developed and tested under the responsibility of Johns Hopkins University.

c) Under the responsibility of the University of Urbino, investigations on the mechanisms of action of the EDS will be conducted with the objective to provide supportive data to the validation of a possible biomarker predictive of treatment efficacy.

d) The ATTEST phase III trial, conducted under the responsibility of EryDel, is an international, multi-center, 1 year, randomized, prospective, double-blind, placebo-controlled, designed to assess the effect of 2 dose ranges of EDS, administered monthly by IV infusion, on neurological symptoms of AT patients.

partners / contact

EryDel S.p.A.

[ EryDel ]

Italy

Giovanni Mambrini

Giovanni Mambrini

Chief Operating Officer EryDel SpA

JOHNS HOPKINS UNIVERSITY

[ JHU ]

United States

Jenny Wright

Jenny Wright

MEDICAL RESEARCH INFRASTRUCTURE DEVELOPMENT AND HEALTH SERVICES FUND BY THE SHEBA MEDICAL CENTER

[ Sheba ]

Israel

Andreea Nissenkorn

Andreea Nissenkorn

Pediatric Neurologist Head of Service for Rare Disorders Pediatric Neurology Unit Safra Children Hospital , Sheba Med

JOHANN WOLFGANG GOETHE UNIVERSITAET FRANKFURT AM MAIN

[ GUF ]

Germany

Stefan Zielen

Stefan Zielen

Universita' degli Studi di Urbino Carlo Bo

[ UNIURB ]

Italy

Mauro Magnani

Mauro Magnani

THE ATAXIATELANGIECTASIA SOCIETY

[ A-T Society ]

United Kingdom

Penny Jeggo

Penny Jeggo

ABSISKEY CP

[ ABSISKEY ]

France

Olivier GUERARD

Olivier GUERARD

This project has received funding from the European Union’s Horizon 2020 research and innovation programme under grant agreement No 667946 . This publication [communication] reflects the views only of the author, and the Commission cannot be held responsible for any use which may be made of the information contained therein.

graph - chart

Start 01/01/2016
100%
End 28/02/2021
Budget allocation . M€ Budget allocation
Effort 322 p*m Effort
Effort 5 persons Full time equivalent

news

IEDAT General Assembly May 2020

2020-05-14

The consortium met remotely at the IEDAT General Assembly #5, on May 14th 2020. During the meeting, the latest achievements of the projec...

View more

IEDAT General Assembly June 2019

2019-06-06

The consortium met remotely at the IEDAT General Assembly #4, on June 6th 2020. During the meeting, the latest achievements of the p...

View more

IEDAT General Assembly 2018

2018-11-28

The consortium will meet in Naples to discuss and share the latest achievements of the project, and the ongoing clinical study, just befo...

View more

IEDAT General Assembly 2017

2017-10-13

The IEDAT consortium will meet in Stansted (London) next October, for the second General Assembly, an important step for the project, whi...

View more

Ataxia Telangiectasia clinical research conference

2016-10-06

IEDAT Consortium will  attend and will be involved in different sessions as speakers during the meeting of the Ataxia Telangiectasia...

View more

Investigator Meeting

2016-01-12

January, 2016 - Investigator meeting of the IEDAT H2020 project organised by Erydel.

View more

EryDel Consortium Gains €6 million of EU Funding

2016-01-07

EU Funding for development of EDS for the treatment of Ataxia Telangiectasia (AT).

On behalf of the IEDAT Consortium, EryDel S...

View more

events

2021-09-04

AT Family weekend in Tivoli, Italy

"Update on the clinical trial AtteST", by Mauro Magnani, PhD.

2021-08-25

Systems Biology and Systems Physiology: regulation of biological networks

With a presentation "Red Blood Cells-based Drug Delivery: New applications and Current Clinical Developments" by Mauro Magnani  

2021-08-04

IEDAT Final Webinar

The final webinar has taken place on August 4th, at 2:30pm.

More details on the public deliverable D7.6 Final evaluation workshop.

2020-10-21

CT³N Seminar

Center for Targeted Therapeutics and Translational Nanomedicine (CT³N), a seminar entitled “Red Blood Cell-based Drug Delivery: our contribution to new applications and current clinical developments” with Mauro Magnani, PhD.

2020-09-11

ERCS 2020

2020 Meeting of the European Red Cell Society, PAvia online meeting, 11 September 2020.

2019-09-18

SIB 2019 60th CONGRESS

SIB 2019 60th CONGRESS - Italian Society of Biochemistry and Molecular Biology Lecce, September 18 – 20, 2019

2019-06-11

Interregional mapping of SIB Congress

The interregional mapping of SIB (Italian Society of Biochemistry and Molecular Biology) issues between Tuscany, Umbria and Marche took place at Ancona, Italy. The university of Urbino representatives were present at the congress.

2019-05-01

18th Annual International Ataxia-Telangiectasia Workshop

The University of Urbino participated in the International Ataxia-Telangiectasia Workshop, which took place on May 1-4,2019 at the Houston Methodist Research Institute (Texas Medical Center). 

2018-11-29

Ataxia Telangiectasia Clinical Research Conference

Representatives of the IEDAT project participated in the Ataxia Telangiectasia Clinical Research Conference which took place from November 28 to December 1, 2018 in Naples.

2018-11-28

Third General Assembly

Before atteding the A-T Clinical Research Conferences in Naples, the consortium meet to discuss the last achievements of the on-going Clincial Study.

2017-10-13

Second General Assembly IEDAT

2016-11-14

First General Assembly

2016-02-22

IEDAT - Kick Off Meeting

documents

Open-Access Scientific Publications

DDIT4 gene expression is switched on by a new HDAC4 function in ataxia telangiectasia - Research Article, https://faseb.onlinelibrary.wiley.com/doi/full/10.1096/fj.201902039R

Proteomics and transcriptomics analyses of ataxia telangiectasia cells treated with Dexamethasone - https://journals.plos.org/plosone/article?id=10.1371/journal.pone.0195388

The nucleoplasmic interactions among Lamin A/C‑pRB‑LAP2α‑E2F1 are modulated by dexamethasone - https://www.nature.com/articles/s41598-021-89608-3

Transcriptomic profile of ataxia telangiectasia cells treated for 30 days with a low dose of dexamethasone - Scientific article - https://www.tandfonline.com/doi/full/10.1080/26895293.2021.1911863

contact us

By submitting this form, I agree that the information entered may be used for newsletter subscriptions, information requests and statistical analysis that may result. Under no circumstances will these data be transferred to third parties.
To know and exercise your rights, in particular to withdraw your consent to the use of data collected by this form, please consult our general conditions of use.

project netboard login